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The prevalence and natural history of aortic
aneurysms in heart and abdominal organ
transplant patients
Michael J. Englesbe, MD,a Audrey H. Wu, MD, MPH,b Alexander W. Clowes, MD,a and
R. Eugene Zierler, MD,a Seattle, Wash
Objective: The purpose of this study was to document the prevalence and clinical features of aortic aneurysms in heart and
abdominal transplant patients.
Methods: We undertook a retrospective review of 1557 patients who had heart, liver, or kidney transplantation between
January 1, 1987, and December 31, 2000. Aortic aneurysms were identified by computed tomographic scan, ultrasound
scan, or at the time of surgery for rupture. An aortic diameter of 3.5 cm was used as the threshold for the definition of
aneurysmal disease. We compared dichotomous variables with Fisher’s exact test and continuous variables with the
Wilcoxon rank-sum test.
Results: There were 296 heart, 450 liver, and 811 kidney transplants performed on adult patients during the study period.
We identified 18 transplant patients who had an aortic aneurysm (13 heart, three liver, two kidney). Seven patients (41%)
had rupture of the aortic aneurysm, and five of these patients died. There were no deaths from causes other than aortic
aneurysm rupture. The rate of aneurysm rupture was 22.5% per year. Eight patients had the aortic aneurysm repaired
electively with no deaths and no hospital stay greater than 15 days. The mean aortic aneurysm size at rupture was 6.02
0.86 cm, and the smallest aneurysm that ruptured was 5.1 cm. The pretransplant rate of aortic aneurysm expansion was
0.46 cm/y, but this increased to 1.00 cm/y after transplantation (P .08). The rate of aortic aneurysm expansion among
heart transplant patients and abdominal transplant patients was the same (P  .51). The prevalence of aortic aneurysm
was 4.1% in cardiac transplant patients and 0.4% in abdominal transplant patients. Earlier in our series (1987 to 1996),
11% of the cardiac transplant patients were screened for aortic aneurysms, and the prevalence rate of diagnosis was 3.0%.
Screening of cardiac transplant candidates became more frequent in 1997 (87% screened), with an associated increase in
the aortic aneurysm prevalence rate to 5.8% in the patients who were screened.
Conclusion: Aortic aneurysms in cardiac and abdominal transplant patients have an aggressive natural history with high
expansion and rupture rates. Screening transplant patients for aortic aneurysms will increase detection and facilitate
elective repair, which is generally well tolerated. These findings support programs for early detection and elective
treatment of aortic aneurysms in organ transplant patients, particularly those having heart transplants. (J Vasc Surg
2003;37:27-31.)
As survival improves after organ transplantation, a ma-
jor source of morbidity and mortality for these patients will
be comorbid conditions unrelated to the transplant, such as
aortic aneurysms. However, little is known about the nat-
ural history of aortic aneurysms in transplant patients. The
previously published experience is limited to case reports
describing the repair of aortic aneurysms in abdominal
transplant patients1-4 and cardiac transplant patients5-8 and
a few small retrospective studies involving only cardiac
transplant patients.9,10
The purpose of this study was to describe the preva-
lence and clinical features of aortic aneurysms in both heart
and abdominal transplant patients and to identify any dif-
ferences between the two groups. In addition, the changes
in the rate of aneurysm expansion before and after a trans-
plant operation will be documented.
METHODS
Patients included in this study underwent heart, liver,
or kidney transplantation between January 1, 1987, and
December 31, 2000, at the University of Washington
Medical Center and were 18 years of age or older at the
time of the transplant. The diagnosis of an aortic aneurysm
was made by computed tomographic scan, ultrasound scan,
or at the time of surgery for rupture. Permission to carry out
this retrospective review was obtained from the University
of Washington Human Subjects Committee. Patients were
identified through review of medical records. Data ob-
tained included demographic information (gender and age
at transplant), baseline clinical information (type of disease
leading to end-stage organ dysfunction, medical comor-
bidities, cardiac ejection fraction, renal function, and liver
function), data on general clinical course (immunosuppres-
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sive regimen and cause of death), and information specific
to the patient’s aortic aneurysm (method of diagnosis, age
at time of diagnosis, imaging results, and operative re-
ports). We defined an aortic aneurysm as an abdominal
aorta greater than 3.5 cm in diameter.
Baseline characteristics were compared between heart
and nonheart transplant patients with Fisher’s exact test for
dichotomous variables and the Wilcoxon rank-sum test for
continuous variables. Statistical analysis was performed
with SAS v.8.0 (SAS Institute, Cary, NC). The mean rate of
aneurysm expansion (cm/y) was calculated for the total
follow-up period and the pretransplant and posttransplant
periods. Mean expansion rates were also calculated for
patients with heart versus nonheart transplants. Calculation
of a mean expansion rate required a minimum of two
imaging studies performed at least 1 month apart during
the time period of interest.
RESULTS
Two hundred ninety-six heart transplants, 450 liver
transplants, and 811 kidney transplants were performed at
the University of Washington Medical Center between
January 1, 1987, and December 31, 2000. Eighteen aortic
aneurysms were identified among these 1557 patients (13
heart, three liver, and two kidney recipients). Among the
heart transplant patients, the overall prevalence of an aortic
aneurysm being diagnosed was 4.1%. Routine screening for
aortic aneurysms before heart transplantation became more
frequent over time. Before 1997, only 11.0% of heart
transplant patients were screened for aortic aneurysms be-
fore transplantation, but beginning in 1997, 87% of pa-
tients were screened. This practice is reflected by a 3.0%
prevalence of aortic aneurysm diagnosis in heart transplant
recipients for the period from 1987 to 1996 and a 5.8%
prevalence for 1997 to 2000. In contrast, the prevalence of
aortic aneurysm diagnosis in nonheart transplant patients
was 0.4% for the entire study period.
Baseline patient characteristics are shown in Tables I
and II. Fourteen patients (82.4%) were men, with an aver-
age age at transplant of 49.6 22.9 years. Of those whose
medication histories were known, all were treated with
cyclosporine and steroids, and most (80.0%) also received
azothiaprine. Five of the 18 patients died during the fol-
low-up period, and all deaths were related to aneurysm
rupture.
Aneurysm characteristics are shown in Table III. Most
(83.3%) were infrarenal in location. One patient was noted
to have an isolated ascending aortic aneurysm of 5.1 cm in
diameter. Because isolated ascending aortic aneurysm is a
distinct clinical entity and not the focus of this study, this
patient was included in the descriptive data charts but was
excluded from prevalence and rate calculations or statistical
comparisons. Average aneurysm size at the time of diagno-
sis was 4.3  1.3 cm, with the average patient age at the
time of diagnosis being 58.8  6.6 years. Most of the
aneurysms were repaired (five ruptured, eight elective),
with a mean interval from diagnosis to repair of 877.5 
818.8 days. The mean posttransplant follow-up period was
21.6  11.2 months. Seven of 17 patients (41%) had
rupture of the aneurysm. Including the three patients who
presented with rupture, the rate of rupture was 22.5% of
aortic aneurysms per year. This high rate of rupture only
describes the patients in our cohort who had diagnosis of
the aortic aneurysm. The rate of rupture would likely be
lower if the true prevalence of aortic aneurysms in the
cohort was known. Of the seven ruptured aneurysms, two
patients did well after repair, three died after repair, and two
died without repair. Among these patients with ruptured
aortic aneurysms, the mean size at the time of rupture was
6.02  0.86 cm, with the smallest measuring 5.1 cm.
Comparison of characteristics between heart and non-
heart transplant recipients showed that a greater proportion
of heart transplant patients were male (91.7% versus 40.0%;
P .01). There were otherwise no significant differences in
the proportion of patients with diabetes or hypertension, in
age at aneurysm diagnosis, or in aneurysm size at the time
of diagnosis or repair.
Overall and subgroup rates of aneurysm expansion are
shown in Table IV. The overall rate of expansion was
0.83 0.49 cm/y, without significant differences between
rates for heart and nonheart transplant groups. The overall
pretransplant expansion rate was 0.46  0.20 cm/y, in-
creasing to 1.00  0.51 cm/y after transplantation (P 
.08). When analysis was limited to only those subjects with
both pretransplant and posttransplant aneurysm expansion
rates available (n 5), the difference was still not significant
(P  .06).
DISCUSSION
To the best of our knowledge, this study presents the
largest reported series of aortic aneurysms in organ trans-
plant patients and it is the first to describe the clinical course
of aortic aneurysms in abdominal transplant patients. The
data suggest that transplant patients have high rates of
aneurysm rupture and that rupture caries a high risk of
fatality. Seven of 17 aneurysms (41%) ruptured, and all five
deaths that occurred in this series were caused by rupture.
The overall rate of aneurysm rupture was 22.5% per year.
Table I. Baseline characteristics in 18 transplant patients
with aortic aneurysms
Characteristic No.
Male gender 14 (82.4%)
Transplanted organ/diagnosis
Heart 13* (72.2%)
Kidney 2 (11.1%)
Liver 3 (16.7%)
Died 5 (29.4%)
Cause of death related to aortic aneurysm 5 (100%)
Complications after emergent repair for rupture 3 (60%)
Intra-abdominal abscess 1/5
Multisystem organ failure 1/5
Massive stroke (brain death) 1/5
No repair 2 (40%)
*Includes one patient with ascending aortic aneurysm.
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Among the transplant patients with ruptured aneurysms,
the mean aneurysm size at the time of rupture was 6.02 
0.86 cm, with the smallest measuring 5.1 cm. These data
do not support previous observations suggesting that an-
eurysms in transplant patients tend to have rupture at
smaller sizes.9,10 In addition, not enough data were avail-
able to confirm whether aortic aneurysms that ruptured had
a faster rate of expansion than those that did not rupture.
Nonetheless, our data do indicate that the natural history of
aortic aneurysms in transplant patients is unfavorable in
terms of rupture rate.
The pretransplant rate of aneurysm expansion in our
study, 0.46 cm/y, approximates the reported rate of 0.2 to
0.4 cm/y in the general population.11,12 After a transplant
operation, this rate increased to 1.0 cm/y. Although not
statistically significant, there was a trend towards higher
aortic aneurysm expansion rates after transplantation. Ob-
servation of a larger study population is needed to clarify
this relationship. There was no statistical difference be-
tween the heart and nonheart transplant patients with
respect to the rate of posttransplant aneurysm expansion.
There have been other reports of increased rates of aneu-
rysm expansion in cardiac transplant patients, ranging from
0.74 cm/y10 to 1.2 cm/y.9 Previous authors have postu-
lated that increased arterial pressure associated with im-
proved cardiac output after cardiac transplantation may
contribute to aortic aneurysm expansion.10 As expected,
our patients had substantially improved cardiac output after
cardiac transplantation. However, the noncardiac trans-
plant patients also had increased rates of aortic aneurysm
expansion after transplantation despite not having a similar
change in hemodynamics. Therefore, we suggest that the
increased rate of aneurysm expansion may not be the result
of a unique characteristic of cardiac transplant patients but
rather associated with a factor common to transplant pa-
tients, such as immunosuppressive medications. There is
evidence in animal models for an increased rate of aneurysm
expansion with steroid treatment,13 but there are limited
Table II. Natural history of aortic aneurysm in 18 transplant patients
Patient
Transplant
type Diagnosis Gender
Transplant
date
AA diagnosis
date
AA
location
Initial
size
(cm)
Final
size
(cm) Rupture Repair Died
1 Heart Ischemic CM M 7/6/87 7/7/93 IR 5.7 5.7 Yes Yes Yes
2 Heart Ischemic CM M 8/28/90 1/20/00 TAAA 6.6 6.6 Yes Yes No
3 Heart Idiopathic CM M 6/15/97 7/1/97 IR 3.2 5.2 No Yes No
4 Liver Alcoholic Cirr M 6/1/94 11/1/93 IR 5.8 7.0 No Yes No
5 Liver PSC F 6/1/89 12/1/99 IR 4.0 5.1 Yes Yes Yes
6 Heart Ischemic CM M 8/18/99 10/28/99 TAAA 5.5 6.5 No No No
7 Heart Ischemic CM M 9/19/92 4/19/92 IR 3.0 6.5 No Yes No
8 Heart Ischemic CM M 5/15/94 6/23/93 IR 3.7 12.5 No Yes No
9 Kidney Polycystic kidney M 1/1/89 3/1/00 IR 5.0 5.1 No Yes No
10 Heart Ischemic CM M 12/1/99 7/1/97 IR 3.0 6.2 No Yes No
11 Heart Ischemic CM M 6/20/00 1/15/97 IR 4.9 5.5 Yes Yes Yes
12 Heart Ischemic CM M 8/13/00 5/1/00 IR 3.1 3.8 No No No
13 Kidney Renal failure NOS F 4/2/87 1/4/94 IR — — Yes Yes No
14 Liver Cryptogenic Cirr F 8/1/92 1/15/00 IR — — No Yes No
15 Heart Idiopathic CM M 2/10/92 1/23/99 IR — — Yes No Yes
16 Heart Ischemic CM M 1/16/97 8/1/96 IR 3.0 3.8 No No No
17 Heart Idiopathic CM F 10/11/87 6/15/90 IR 4.5 7.2 Yes No Yes
18 Heart Marfan’s M 9/11/95 1/1/91 AscAo 3.5 5.1 No Yes No
M, Male; F, female; CM, cardiomyopathy; Cirr, cirrhosis; PSC, primary sclerosing cholangitis; NOS, not otherwise specified; AA, aortic aneurysm; IR,
infrarenal; TAAA, thoracoabdominal; AscAo, ascending aorta.
Table III. Aortic aneurysm characteristics
Characteristic No.
Age at aortic aneurysm diagnosis (y) 58.8  6.6
Size of aneurysm at time of diagnosis (cm) 4.3  1.3
Size of aneurysm at time of repair/last
study (cm)
6.0  2.1
Aortic aneurysm location
Thoracoabdominal 2 (11.1%)
Infrarenal 15 (83.3%)
Ascending aorta 1 (5.6%)
Aneurysm ruptured 7 (41.2%)
Size at rupture (cm) 6.02  0.86
Aneurysm repaired 13 (81.3%)
Time between aneurysm diagnosis
and repair (d)
877.5  818.8
Method of repair
Open tube 9 (69.2%)
Endovascular 3 (23.1%)
Arch repair 1 (7.7%)
Table IV. Mean rates of aneurysm expansion
Patient type
Aneurysm expansion
rate (cm/y)
All patients (after transplant) 0.83  0.49 (n  12)
Heart transplant patients 0.78  0.41 (n  9)
Nonheart transplant patients 1.00  0.58 (n  3)
Before transplant 0.46  0.20 (n  5)
After transplant 1.00  0.51 (n  12)
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clinical data to support the conclusion that steroids increase
the rate of aneurysm expansion in humans.14,15 The etio-
logic factors predisposing transplant patients to rapid aneu-
rysm expansion and rupture remain undetermined. In ad-
dition to the type of immunosuppressive medications,
frequency of rejection, infection, insulin resistance, lipid
abnormalities, hypertension, and other hemodynamic fac-
tors may all play a role. Additional studies are needed to
further elucidate the unique relationship between post-
transplant status and aortic aneurysms.
The previously reported prevalence of aortic aneurysms
in cardiac transplant patients is in the range of 1% to
4%,5,7,9,10 and the prevalence of aortic aneurysms in men
aged 65 to 80 years in the general population is 4.3% to
7.7%.16,17 Because our study is retrospective and not all
patients were screened to rule out an aortic aneurysm, our
data do not reflect a true prevalence but rather the preva-
lence of aortic aneurysm diagnosis. As a result, it is difficult
to compare our data with these other studies. The preva-
lence of aortic aneurysm diagnosis in our study was 6.2% in
patients who had a heart transplant for ischemic cardiomy-
opathy compared with a prevalence of 2.7% in patients who
had a heart transplant for other indications and a prevalence
of 0.4% in patients who had abdominal organ transplants.
The higher prevalence in patients with ischemic cardiomy-
opathy is most likely associated with the similarities of risk
factors for aortic aneurysms and ischemic cardiomyopathy.
Changes in screening practice patterns appear to have
affected the prevalence of aortic aneurysms in heart trans-
plant patients in our study. Corresponding to the increased
frequency of screening for aortic aneurysms from 1997
onwards, the prevalence of diagnosis increased from 3.0%
to 5.8%. The earlier (1987 to 1997) and later (1997 to
2000) groups of heart transplant patients were not signifi-
cantly different with regard to mean age at transplant,
presence of comorbidities, or proportion with ischemic
cardiomyopathy. None of the patients who had the aortic
aneurysm found during the latter period when screening
was more common died of aneurysm rupture.
Elective repair of aortic aneurysms in transplant pa-
tients can be performed safely, with minimal morbidity and
mortality. In this series, eight patients underwent elective
repair without any fatalities. Postoperative morbidity in-
cluded long-term hemodialysis in one patient and a type II
endoleak after endovascular repair in another patient. No
patient needed greater than 15 days of hospitalization after
elective aneurysm repair. In addition, in our series, all of the
transplant patients had normal ejection fractions and toler-
ated aortic cross clamping in the cases of open repairs.
CONCLUSION
Aortic aneurysms are a significant clinical problem in
organ transplant patients. Compared with patients without
transplant, aortic aneurysms in abdominal and heart trans-
plant patients expand more than twice as rapidly. Aortic
aneurysms that have been diagnosed in transplant patients
have a high rate of rupture, and aneurysm rupture in
transplant patients is associated with poor outcomes. Fi-
nally, transplant patients appear to do well after elective
aortic aneurysm repair. On the basis of these findings, we
conclude that early diagnosis and treatment of aortic aneu-
rysms in transplant patients is critical. At the time of initial
pretransplant evaluation, we recommend a protocol of
screening all cardiac transplant patients over 45 years of age
or with ischemic cardiomyopathy. Patients having abdom-
inal transplants do not need to be screened. When a small
aortic aneurysm is found in a transplant patient, we recom-
mend close surveillance (imaging every 6 months) and
prompt repair of all aortic aneurysms 5.0 cm in diameter or
larger.
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DISCUSSION
Dr Mitchell H. Goldman (Knoxville, Tenn). You happened
to hit an area that I have a little bit of interest in, both from the
vascular and the transplant side. One of the questions I have is, are
you recommending that your patients with cardiomyopathy at age
25 be screened for abdominal aortic aneurysm, or is there an age as
well as a diagnosis which would help us to differentiate which
patients should be screened?
Also, what is the role of antihypertensives in both the abdom-
inal and the heart transplant population? Both cyclosporine and
FK506 are quite well known for their induction of hypertension
and that, more than the immunosuppressive effect may, in fact, be
the etiology for your expansion rate and your rupture rate.
Finally, in the abdominal transplant patients, was there a
difference between atherosclerotic etiologies for renal failure and,
say, glomerulonephritis or diabetes?
Dr Michael J. Englesbe. With respect to your first question,
if a 25-year-old with cardiomyopathy presents for transplant, do
they need screening for an aneurysm? The answer is no. The
patients that I think we should screen are those who have ischemic
cardiomyopathy, which generally is about half of heart transplant
candidates. Patients who have other indications for transplantation
do not need to be screened unless they are old enough to be at risk
for aortic aneurysm.
Your point regarding hypertension is an excellent one but
something we did not consider. We did not sufficiently evaluate
differential blood pressures pretransplant and posttransplant. Pa-
tients who are on a heart transplant list tend to be relatively
hypotensive, but they usually become hypertensive after transplan-
tation, most likely due to increased cardiac output or the immu-
nosuppressant medications.
Regarding your third question, there were only two renal
transplant patients, and both of them had a primary (nonathero-
sclerotic) nephropathy.
Dr John W. Hallett, Jr (Bangor, Me). Given the relatively
rapid expansion rate that you have seen, are you changing your
recommendation to patients with 4-cm to 5-cm aneurysms who
are headed into a transplant; in other words, are you recommend-
ing that they have the aneurysm repaired before they go on
immunosuppressive drugs?
Dr Englesbe. I think that is a good question. It is one that we
struggled with.
We noted that the smallest aneurysm that ruptured in our
series was 5.1 cm. Thus, we do not suggest repairing any aneu-
rysms less than 5 cm.
There are some data showing that patients who have small
aneurysms, 4-cm to 6-cm, do well with repair following heart
transplantation, as compared with having aneurysm repair prior to
their transplant. So, we suggest, if possible, delaying surgery until
after cardiac transplantation and aneurysm repair promptly there-
after. If the patient has an aneurysm smaller the 5 cm, I would
explain to them that little data are available and I would encourage
close follow-up.
Dr M. David Tilson (New York, NY). I have two comments.
One is that other primates get aneurysms. Interestingly enough,
aneurysm is unknown in the orangutan, but it is the second leading
cause of cardiovascular death in the western lowland gorilla. The
leading cause of death is cardiomyopathy. So, one interpretation
that would be a little different would be that the heart transplant
patients have preselected a subset that might be more aneurysm-
prone. So, that is just a speculation, but it is something to keep in
mind.
The second is that you have talked about immunosuppression
and its possible role on the promotion of aneurysm development.
If our notions turn out to be correct, that autoimmunity plays an
important role in the development of the AAA, then it would be
counterintuitive that immunosuppression might be the predispos-
ing factor.
However, John Gertler, who might be in the audience, when
he was a youngster in my lab quite a few years ago, showed that
aneurysms do not occur in the heterozygous female aneurysm-
prone Blotchy mouse. But in some experiments we did, actually
addressing another experimental question, it turned out that a very
large number of female heterozygous aneurysm-prone mice devel-
oped aneurysms and ruptured on hydrocortisone. So, I think
among the candidate interventions that might be influencing this
natural history after transplantation, that the steroids would be
better candidates than the immunosuppressants.
I am sorry it is not really a question, but it is a comment and I
would enjoy your response
Dr Englesbe. Thank you for your insightful comments. Ob-
viously, there are very few cardiac transplant programs that do not
give their patients steroids, so that issue will be tough to study.
AVAILABILITY OF JOURNAL BACK ISSUES
As a service to our subscribers, copies of back issues of Journal of Vascular Surgery for the preceding
5 years are maintained and are available for purchase from Mosby until inventory is depleted. Please write
to Mosby, Subscription Customer Service, 6277 Sea Harbor Dr, Orlando, FL 32887, or call 800-654-
2452 or 407-345-4000 for information on availability of particular issues and prices.
JOURNAL OF VASCULAR SURGERY
Volume 37, Number 1 Englesbe et al 31
